Riku Heikki Rautsola

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

Elbion NV discovers and develops therapeutics for neurological diseases and immunological disorders. It focuses on the discovery and development of new drugs for CNS and immunological diseases. The company was founded by Dr. Thomas Kronbach and Dr. Bernd Kastler in 2002 and is headquartered in Leuven, Belgium.

Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom.

Hapten Sciences, Inc. is a biopharmaceutical company. It identifies and develops novel, early-stage products that contribute to the health and well being of people around the world. Its product include PDC-APB, a small molecule that acts like a vaccine to prevent the extremely painful itching and rash. The company was founded by Raymond Joseph Hage Jr. and is headquartered in Memphis, TN.

Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California.

TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.

RIEMSER Pharma GmbH develops, manufactures and distributes pharmaceutical products. It operates as an international specialty pharmaceutical company and core competencies cover the areas oncology, particularly supportive therapies, anti-infectives and dermatology. The company was founded in 1992 and is headquartered in Greifswald, Germany.

Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Part of GSK Plc, Sterling Winthrop, Inc. is a company that specializes in cameras and duplicating machines. The company is based in Rochester, NY. Sterling Winthrop was acquired by GSK Plc from Eastman Kodak Co. on November 03, 1994 for $2,930 million.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

Odewald & Compagnie Gesellschaft für Beteiligungen mbH (Odewald) is a private equity firm founded in 1997 by Dr. Jens Odewald. The firm is headquartered in Berlin.

DelSiTech Ltd develops therapeutic delivery technology and drug formulations. Its services include small molecule drug delivery, delivery solutions for biological macromolecus, virus vector delivery, manufacturing service, and analytical service. The company was founded by Harry Jalonen in 2001, and is headquartered in Turku, Finland.

Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Oberbergkliniken GmbH engages in the operation of acute care clinics. It specializes in the medical and psychotherapeutic treatment of patients that suffer from mental, psychosomatic, and psychiatric diseases. The company was founded by Edda Gottschaldt and Matthias Gottschaldt in 1988 and is headquartered in Berlin, Germany.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

OMOS Equity Partners GmbH provides investment services. It offers services for major change processes, development and assessment of policy options and scenarios, speech and implementation of transactions, and content solutions. The firm focuses on the health sector, industry sector, and service and logistics sector. The company was founded on July 22, 2014 and is headquartered in Berlin, Germany.

Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Heinrich Höpner GmbH & Co. KG provides business support services. The private company is based in Hamburg, Germany. The CEOs are Christoph Schröder, Thomas Schröder. The German company was founded in 1913.

Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA.

ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada.